NCT05632887

Brief Summary

Eyeliner is one of the most common eye cosmetics. The main ingredients are titanium oxide, pigment, grease and preservative. The user will apply the eyeliner to the eyelid and eyelash. With the blinking again and again, the components of the eyeliner may enter the tear film and continue to act on the eye surface. Therefore, the investigators suspect that the use of eyeliner may be an important factor leading to dry eye disease. In order to explore the relationship between the use of eyeliner and dry eye disease, the investigators plan to collect eye surface characteristic data of the two groups of people who use eyeliner and who do not use it.Then use Raman analysis to explore whether the use of eyeliner will lead to changes in tear composition.The investigators intend to analyze the difference of tear composition between the two groups to understand the relationship between the change of tear composition and tear film stability.So that the investigators can identify the risk factors of dry eye disease, and provide basis for prevention and early treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
2mo left

Started Nov 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
Nov 2022Sep 2026

First Submitted

Initial submission to the registry

October 9, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

November 20, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 1, 2022

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2026

Expected
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2026

Last Updated

September 29, 2025

Status Verified

September 1, 2025

Enrollment Period

3.8 years

First QC Date

October 9, 2022

Last Update Submit

September 23, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • The Schirmer's test evaluates aqueous tear production.

    Schirmer test is a simple method to measure the amount of tear secretion.It is helpful in the assessment of patients with signs and/or symptoms of dry eye as it can determine whether surface dryness is due to reduced tear production from the lacrimal glands as opposed to some other cause.Normal aqueous tear production is supported by measurements of \> 15 mm after 5 minutes.Mild-moderate reduction of aqueous production: 5mm-14mm after 5 minutes.Severe dryness due to reduced tear production is \<5mm after 5 minutes.

    baseline

  • The gland loss assessed by meibography images.

    The investigators can observe the morphology of meibomian gland to grade the degree of Dry Eye.The morphology was evaluated by analyzing meibography images obtained with the non-contact infrared meibography system OCULUS Keratograph 5.MG loss in each eyelid was evaluated subjectively using a four-point grading scale (meibograde) of 0-3described as : grade 0: 0-25% loss; grade 1: 26-50% loss; grade 2: 51-75% loss; and grade 3: \>75% loss.

    baseline

  • Evaluation of lipid content and ionic composition in tears by raman analysis.

    The investigators can use Raman spectroscopy to compare the changes of tear composition between the two groups.Raman spectroscopy is a technique that detects vibrational motions in molecules and can be used for lipids. It is a powerful technique and often used when analyzing biological samples such as lipids and proteins because it's non-invasive, highly accurate, insignificant amount and provides abundant chemical information.The fatty acids, triglycerides, phospholipids, sphingolipids, cholesterol and carotenoids can be detected.And the investigators can use a special instruments to test Na+,K+,Mg2+ and Cl- those are very important in tear film homeostasis.

    baseline

Study Arms (2)

Control

The population who do not use eyeliner.

Other: no intervention

Eyeliner

The population who using eyeliner and the duration and frequency are appropriate。

Other: no intervention

Interventions

no intervention

ControlEyeliner

Eligibility Criteria

Age20 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The main population of our study is the young women who do not have other diseases that affect the health of eye surface and use or do not use eyeliner.

You may qualify if:

  • People aged 20-35 who use eyeliner or do not use eyeliner .
  • People who use eyeliner have used it for ≥ 1 year; Frequency ≥ 3 times/week.

You may not qualify if:

  • Other serious systemic diseases.
  • Other systemic diseases related to ocular surface, such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome and other immune system diseases or other eye diseases, history of eye surgery and trauma.
  • Lactating women or pregnant women.
  • Use electronic products for more than 4 hours every day.
  • Patients with circadian rhythm disorder.
  • People with radiation exposure history.
  • Non permanent residents in Wuhan.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

tears

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Study Officials

  • Min Ke

    Ophthalmology Department of Zhongnan Hospital of Wuhan University

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 9, 2022

First Posted

December 1, 2022

Study Start

November 20, 2022

Primary Completion (Estimated)

September 15, 2026

Study Completion (Estimated)

September 30, 2026

Last Updated

September 29, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations